Gentium (GENT -1%) announces an agreement with National University, Hamamatsu University School of Medicine, Fukushima Medical University and LINK Healthcare to support a Phase I clinical trial of its Defibrotide anti-clotting drug candidate. Under the terms of the agreement, (GENT) will provide free drug and technical support and LINK will provide administrative and logistical support for the clinical trial conducted by HUSM.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs